HeartBeam Inc. (NASDAQ: BEAT) has announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, known as ischemia. This development comes as coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs.
The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets. According to HeartBeam CEO Robert Eno, “Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time. The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG for ischemia detection could transform how healthcare providers identify high-risk patients earlier.”
Cardiovascular risk factors are becoming more common as populations age, intensifying the seriousness of coronary artery disease. Healthcare providers are searching for faster and more accessible ways to identify high-risk patients before a major cardiac event occurs. The HeartBeam patch aims to address this need by providing clinical-grade insights over an extended period, which current patch-based ambulatory monitors cannot offer.
The implications of this study are significant for the healthcare industry and patients alike. If successful, the HeartBeam patch could enable earlier detection of coronary artery disease and ischemia, potentially reducing the number of silent heart attacks and improving patient outcomes. For the industry, it could disrupt the existing $2 billion market for long-term continuous monitors and MCT devices, offering a new standard of care for ambulatory cardiac monitoring.
HeartBeam’s latest news and updates are available in the company’s newsroom at https://nnw.fm/BEAT. The company continues to advance its technology with the goal of providing innovative solutions for cardiac care.
This pilot study marks a crucial milestone for HeartBeam as it seeks to validate its technology and bring a new tool to the fight against coronary artery disease, which remains a leading cause of death globally. The outcomes of this study will be closely watched by investors, healthcare providers, and patients who stand to benefit from improved diagnostic capabilities.
